Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
| Drug | Drug Name | Drug Description |
|---|
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB16669 | Surzebiclimab | 1 / 2 | Recruiting | 1 |
| DB14922 | Tislelizumab | 1 / 2 | Recruiting | 1 |